ACUTE MYELOID LEUKEMIA REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to beat High-Risk leukemia and MDS
Disease control Recruiting nowThis phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New CAR t cell therapy targets Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune cell combo targets stubborn leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) immune cells with a drug called atezolizumab. The main goal is to find a…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard treatments, in adults with acute myeloid leukemia (AML) or related blood disorders. The goal is to find a safe dose and see if it shrinks cancer. About 100 people will take part.
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental ceramide therapy takes on tough leukemia
Disease control Recruiting nowThis early-stage trial tests a new drug called C6 ceramide nanoliposome (Ceraxa) in 15 adults with acute myeloid leukemia that has come back or not responded to treatment. The drug is given by IV twice a week, and the main goal is to check safety and find the right dose. It is to…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for young AML patients: drug cocktail targets resistant cancer
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 40 participants will receive different doses of venetoc…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New immune therapy offers hope for kids with stubborn leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in the lab to bett…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for tough blood cancers: ARD103 trial opens
Disease control Recruiting nowThis study tests a new drug called ARD103 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink or c…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for tough leukemia? early trial tests AB8939
Disease control Recruiting nowThis early-phase trial is testing a new drug called AB8939, given daily through a vein, for people with acute myeloid leukemia that has come back or not responded to standard treatments. About 78 participants will receive AB8939, sometimes with another drug called venetoclax. The…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Massive study to track what happens when AML comes back
Knowledge-focused Recruiting nowThis observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC